On November 16, 2023, according to the notice from the National Organization Joint Procurement Office, our company's product Calcium Gluconate Sodium Chloride Injection was qualified to be selected in the National Drug Centralized Procurement (GY-YD2023-2). We will be main supplier for: Yunnan and Sichuan , Guizhou, Hebei, and Hainan provinces, we will be standby supplier for: Hunan, Shandong, Jilin, Jiangxi, and Qinghai provinces. The supply period is from 2024 to 2027.

It is our first time to win the bid this time, and obtained the largest share of this product in the national public institutional market. Our company will actively organize production and strictly control product quality. Complete supply with guaranteed quality and quantity.

Genchain's early product portfolio mainly revolves around the new national drug reform policy. It is expected that nearly 30 of the company's more than 40 projects are expected to catch up with the country's first batch of centralized procurement. Through centralized procurement, Genchain can become one of the main supplier with a large share of my country's medical institutions market in the next five years. In order to achieve sustainable development, the company is currently planning to introduce international elements. On the one hand, it will graft international resources in raw material procurement, research and development and other aspects, enter the field of complex generic drug development, and selectively intervene in the blue ocean track. On the one hand, it explores the licensing introduction path, introduces innovative drugs from Europe and other regions in a timely manner, and uses a differentiated strategy to enhance Genchain's competitiveness in the domestic pharmaceutical market. At the same time, relying on Hainan's location advantages and free trade zone policy support, we are targeting international markets such as Southeast Asia and Europe in product development and design, product clinical layout, production system and quality system construction, market expansion, etc., becoming a globally competitive industry. and brand reputation of pharmaceutical companies.